跳至主要内容
临床试验/NCT07533357
NCT07533357尚未招募不适用

A Prospective Study of Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Fudan University0 个研究点目标入组 158 人开始时间: 2026年4月20日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
158
主要终点
overall survival

研究概览

简要总结

The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have longer overall survival. The main question it aims to answer is: Whether precursor exhausted T cells (Tpex) in negative tumor-draining lymph nodes have better predictive efficacy for treatment response than PD-L1 CPS.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥18 years
  • Histologically confirmed esophageal carcinoma
  • Clinical stages IV based on the 8th AJCC TNM classification, or recurrent esophageal cancer
  • plan to treated with PD-1 immunotherapy
  • Eastern Cooperative Oncology Group(ECOG) performance status: 0-2

排除标准

  • Esophageal perforation or hematemesis
  • Any active autoimmune disease or a history of autoimmune disease
  • Disease progression occurs within 3months after PD-1 immunotherapy.
  • Allergic to macromolecular protein preparations, or to any of the ingredients in PD-1 inhibitors for injection.
  • Uncontrolled heart diseases or clinical symptoms
  • Congenital or acquired immunodeficiency (such as HIV infection); active hepatitis B (HBV-DNA≥104 copy number/ml) or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the detection limit of the analytical method); active tuberculosis.

研究组 & 干预措施

PD-1 treatment group

PD-1 treatment group

结局指标

主要结局

overall survival

时间窗: 2 years

overall survival

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kuai Le Zhao, MD

Prof.

Fudan University

相似试验

Tpex Subsets in Negative Tumor Draining Lymph Nodes... | 临床试验